NeoTYPE® Follicular Lymphoma Profile

Conventional follicular lymphoma (FL) is a common form of non-Hodgkin lymphoma (NHL) that stems from germinal center B-lymphocytes and is typically characterized by diffuse lymphadenopathy, splenomegaly, and bone marrow involvement, as well as occasional involvement in other extranodal sites. Histologic grade correlates with prognosis with grade 1-2 being indolent and not usually curable. Grade 3 conventional FL has a more aggressive clinical course, but may respond to systemic therapies. Frequent recurrent genetic abnormalities in conventional FL include rearrangements of BCL2 (80%) and BCL6 (15%).

Pediatric-type follicular lymphoma (PTFL) most commonly presents in children age 7.4-14 years, but can be seen in young adults and more rarely older adults. PTFL occurs as localized disease of the head and neck lymph nodes or tonsils and is characteristically negative for BCL2 and BCL6 rearrangements. Although most cases meet conventional criteria for grade 3B FL, PTFL has a good prognosis after local excision alone. The molecular profile of PTFL differs from conventional FL, as PTFL only has rare mutations in CREBBP, EZH2 and KMT2D, which are commonly found in conventional FL. PTFL frequently has mutations in TNFRSF14 and MAP2K1. Follicular lymphoma with EZH2 mutation may respond to EZH2 inhibitors. The NeoTYPE^® Follicular Lymphoma Profile has been developed to include a number of genes which are associated with lymphoma pathogenesis. Results from this test will aid in patient diagnosis, classification, prognosis, as well as treatment decisions.